Toward this goal, we decided first to better study the OSCC tumor microenvironment in terms of cell subpopulations and relevant markers of immunity to get hints of the importance of CD4+ TH cells in a clinical setting, and then to assess in an in vivo animal experimental model of OSCC the efficacy of an anti-tumor vaccination focused on the optimal activation of tumor specific TH cells. Here, CD4 is linked to neoplasm.